Rahuldev Bhalla, MD, a fellowship-trained board-certified urologist, joined the combined medical group of RWJBarnabas Health and Rutgers Health, the systems said March 10. Dr. Bhalla will provide ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...

Urologic oncologist Dr. Isaac Powell sits down with TODAY’s Al Roker to discuss his research into why Black men are more likely to be diagnosed with and die from prostate cancer. He talks about ...

Please provide your email address to receive an email when new articles are posted on . NASHVILLE, Tenn. — Alexander Kutikov, MD, FACS, received Kidney Cancer Association’s Andrew C. Novick Award. The ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC). This ...

Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters IRVINE, Calif., Nov. 20, 2024 ...

CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (RLMD) (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative ...

Quantifying publication rates and time to publication for urologic oncology podium presentations. Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): ...